| 45 | 46 | | |
|---|
| 46 | 47 | | |
|---|
| 47 | 48 | | |
|---|
| 48 | 49 | | |
|---|
| 49 | 50 | | |
|---|
| 50 | 51 | | |
|---|
| 51 | 52 | | |
|---|
| 52 | 53 | | An Act |
|---|
| 53 | 54 | | |
|---|
| 54 | 55 | | |
|---|
| 55 | 56 | | |
|---|
| 56 | 57 | | amending section 32-1970, Arizona Revised Statutes; relating to the Arizona state board of pharmacy. |
|---|
| 57 | 58 | | |
|---|
| 58 | 59 | | |
|---|
| 59 | 60 | | |
|---|
| 60 | 61 | | |
|---|
| 61 | 62 | | |
|---|
| 62 | 63 | | (TEXT OF BILL BEGINS ON NEXT PAGE) |
|---|
| 63 | 64 | | |
|---|
| 64 | 65 | | |
|---|
| 65 | 66 | | |
|---|
| 66 | 67 | | Be it enacted by the Legislature of the State of Arizona: Section 1. Section 32-1970, Arizona Revised Statutes, is amended to read: START_STATUTE32-1970. Collaborative practice agreements; requirements; rules; definitions A. A pharmacist who is licensed pursuant to this chapter may enter into a collaborative practice agreement with a provider pursuant to this section to initiate, monitor and modify drug therapy or provide disease management assistance. The collaborative practice agreement may be between one or more pharmacists and one or more providers. The collaborative practice agreement shall: 1. Outline the duties related to drug therapy and disease management that the provider is delegating to the pharmacist to perform, including drug therapy that the pharmacist may initiate, monitor and modify and laboratory tests that the pharmacist may order, and the eligible group of patients that may be treated under the collaborative practice agreement. 2. Specify, at a minimum, the conditions to be managed by the pharmacist through disease management and drug therapy management, the circumstances for which the pharmacist must notify the provider and any documentation or recordkeeping requirements. 3. Specify that the pharmacist must follow the written drug therapy and disease management guidelines provided by the provider and may provide drug therapy and disease management services only pursuant to those guidelines. The guidelines shall specify, at a minimum, the specific drug, drugs or drug classes and the conditions to be managed by the pharmacist, the conditions and events for which the pharmacist must notify the provider and the laboratory tests the pharmacist may order. B. A provider who enters into a collaborative practice agreement under this section must have a previously established provider-patient relationship with a patient in order for that patient to be a part of the eligible group of patients who may be included under the collaborative practice agreement. C. A licensee who violates this section commits an act of unprofessional conduct. D. A pharmacist is responsible for the pharmacist's negligent acts that are the result of the clinical decisions made pursuant to the collaborative practice agreement. This subsection does not limit a provider's liability for negligent acts that are not related to a pharmacist's change of medication pursuant to the collaborative practice agreement. E. The pharmacist shall maintain a copy of the collaborative practice agreement and make the collaborative practice agreement available to the board on request. F. The Arizona state board of pharmacy, the Arizona medical board, the Arizona board of osteopathic examiners in medicine and surgery and the Arizona state board of nursing may adopt rules relating to collaborative practice agreements. G. For the purposes of this section: 1. "Collaborative practice agreement" means an agreement between a pharmacist and a provider that outlines the drug therapy and disease management services, including initiating, monitoring and modifying prescription drug and laboratory test orders, that are authorized by the provider and delegated to the pharmacist for the purposes of drug therapy management or disease management based on the pharmacist's skills or training. 2. Initiate, monitor and modify does not include a pharmacist's selection of drug products that are not prescribed by the provider unless the selection of specific drug products is authorized by the collaborative practice agreement. 3. "Provider" means a physician who is licensed pursuant to chapter 13 or 17 of this title, or a registered nurse practitioner or certified nurse midwife who is licensed pursuant to chapter 15 of this title or a physician assistant who is licensed pursuant to chapter 25 of the title.END_STATUTE |
|---|
| 67 | 68 | | |
|---|
| 68 | 69 | | Be it enacted by the Legislature of the State of Arizona: |
|---|
| 69 | 70 | | |
|---|
| 70 | 71 | | Section 1. Section 32-1970, Arizona Revised Statutes, is amended to read: |
|---|
| 71 | 72 | | |
|---|
| 72 | 73 | | START_STATUTE32-1970. Collaborative practice agreements; requirements; rules; definitions |
|---|
| 73 | 74 | | |
|---|
| 74 | 75 | | A. A pharmacist who is licensed pursuant to this chapter may enter into a collaborative practice agreement with a provider pursuant to this section to initiate, monitor and modify drug therapy or provide disease management assistance. The collaborative practice agreement may be between one or more pharmacists and one or more providers. The collaborative practice agreement shall: |
|---|
| 75 | 76 | | |
|---|
| 76 | 77 | | 1. Outline the duties related to drug therapy and disease management that the provider is delegating to the pharmacist to perform, including drug therapy that the pharmacist may initiate, monitor and modify and laboratory tests that the pharmacist may order, and the eligible group of patients that may be treated under the collaborative practice agreement. |
|---|
| 77 | 78 | | |
|---|
| 78 | 79 | | 2. Specify, at a minimum, the conditions to be managed by the pharmacist through disease management and drug therapy management, the circumstances for which the pharmacist must notify the provider and any documentation or recordkeeping requirements. |
|---|
| 79 | 80 | | |
|---|
| 80 | 81 | | 3. Specify that the pharmacist must follow the written drug therapy and disease management guidelines provided by the provider and may provide drug therapy and disease management services only pursuant to those guidelines. The guidelines shall specify, at a minimum, the specific drug, drugs or drug classes and the conditions to be managed by the pharmacist, the conditions and events for which the pharmacist must notify the provider and the laboratory tests the pharmacist may order. |
|---|
| 81 | 82 | | |
|---|
| 82 | 83 | | B. A provider who enters into a collaborative practice agreement under this section must have a previously established provider-patient relationship with a patient in order for that patient to be a part of the eligible group of patients who may be included under the collaborative practice agreement. |
|---|
| 83 | 84 | | |
|---|
| 84 | 85 | | C. A licensee who violates this section commits an act of unprofessional conduct. |
|---|
| 85 | 86 | | |
|---|
| 86 | 87 | | D. A pharmacist is responsible for the pharmacist's negligent acts that are the result of the clinical decisions made pursuant to the collaborative practice agreement. This subsection does not limit a provider's liability for negligent acts that are not related to a pharmacist's change of medication pursuant to the collaborative practice agreement. |
|---|
| 87 | 88 | | |
|---|
| 88 | 89 | | E. The pharmacist shall maintain a copy of the collaborative practice agreement and make the collaborative practice agreement available to the board on request. |
|---|
| 89 | 90 | | |
|---|
| 90 | 91 | | F. The Arizona state board of pharmacy, the Arizona medical board, the Arizona board of osteopathic examiners in medicine and surgery and the Arizona state board of nursing may adopt rules relating to collaborative practice agreements. |
|---|
| 91 | 92 | | |
|---|
| 92 | 93 | | G. For the purposes of this section: |
|---|
| 93 | 94 | | |
|---|
| 94 | 95 | | 1. "Collaborative practice agreement" means an agreement between a pharmacist and a provider that outlines the drug therapy and disease management services, including initiating, monitoring and modifying prescription drug and laboratory test orders, that are authorized by the provider and delegated to the pharmacist for the purposes of drug therapy management or disease management based on the pharmacist's skills or training. |
|---|
| 95 | 96 | | |
|---|
| 96 | 97 | | 2. Initiate, monitor and modify does not include a pharmacist's selection of drug products that are not prescribed by the provider unless the selection of specific drug products is authorized by the collaborative practice agreement. |
|---|
| 97 | 98 | | |
|---|
| 98 | 99 | | 3. "Provider" means a physician who is licensed pursuant to chapter 13 or 17 of this title, or a registered nurse practitioner or certified nurse midwife who is licensed pursuant to chapter 15 of this title or a physician assistant who is licensed pursuant to chapter 25 of the title.END_STATUTE |
|---|